Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2026,
Thermo Fisher Scientific paidR$15,689 Mil more to buy back shares than it received from issuing new shares.
It receivedR$22,043 Mil from issuing more debt.
It paidR$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It spentR$847 Mil paying cash dividends to shareholders.
It receivedR$209 Mil on other financial activities.
In all, Thermo Fisher ScientificearnedR$5,716 Mil on financial activities for the
three
months ended in Mar. 2026.
Thermo Fisher Scientific (BSP:TMOS34) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Thermo Fisher Scientific's issuance of stock for the
three
months ended in Mar. 2026 was R$0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Thermo Fisher Scientific's repurchase of stock for the
three
months ended in Mar. 2026 was R$-15,689 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Thermo Fisher Scientific's net issuance of debt for the
three
months ended in Mar. 2026 was R$22,043 Mil.
Thermo Fisher Scientific receivedR$22,043 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Thermo Fisher Scientific's net issuance of preferred for the
three
months ended in Mar. 2026 was R$0 Mil.
Thermo Fisher Scientific paidR$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Thermo Fisher Scientific's cash flow for dividends for the
three
months ended in Mar. 2026 was R$-847 Mil.
Thermo Fisher Scientific spentR$847 Mil paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Thermo Fisher Scientific's other financing for the
three
months ended in Mar. 2026 was R$209 Mil.
Thermo Fisher Scientific receivedR$209 Mil on other financial activities.
Thermo Fisher Scientific Cash Flow from Financing Related Terms
Thermo Fisher Scientific Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Thermo Fisher Scientific's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thermo Fisher Scientific Cash Flow from Financing Chart
Thermo Fisher Scientific Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Thermo Fisher Scientific's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$16,067 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of R$16,067 Mil mean?
Thermo Fisher Scientific (BSP:TMOS34) has a Cash Flow from Financing of R$16,067 Mil as of Mar. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Thermo Fisher Scientific and its competitors.
Is Thermo Fisher Scientific's Cash Flow from Financing too high?
Thermo Fisher Scientific's current Cash Flow from Financing is R$16,067 Mil. Overall, Thermo Fisher Scientific has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Thermo Fisher Scientific's Cash Flow from Financing compare to DHR and IDXX?
Thermo Fisher Scientific's Cash Flow from Financing of R$16,067 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Medical Diagnostics & Research company?
A good Cash Flow from Financing depends on the Medical Diagnostics & Research industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Thermo Fisher Scientific and its competitors. Thermo Fisher Scientific's current Cash Flow from Financing is R$16,067 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thermo Fisher Scientific stock overvalued right now?
Based on GuruFocus' analysis, Thermo Fisher Scientific (BSP:TMOS34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$61.98, compared to a current price of R$55.81 — trading 10% below its estimated fair value. The current Cash Flow from Financing is R$16,067 Mil. Thermo Fisher Scientific's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Thermo Fisher Scientific (BSP:TMOS34), the current Cash Flow from Financing is R$16,067 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thermo Fisher Scientific (BSP:TMOS34) Overvalued in 2026?
Based on GuruFocus' analysis, Thermo Fisher Scientific stock appears to be undervalued.
The current stock price of R$55.81 is trading 10% below its estimated GF Value™ of R$61.98.
GuruFocus considers Thermo Fisher Scientific to be Modestly Undervalued.
Key valuation signals for BSP:TMOS34:
Cash Flow from Financing: R$16,067 Mil
GF Value™: R$61.98 vs. price of R$55.81 (10% below fair value)
No single metric tells the full story. See the BSP:TMOS34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
74GF Score
Get the complete analysis for BSP:TMOS34
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:TMOS34 has been successfully added to your 
